SCHEMBL20480552

SCHEMBL20480552

COC(=O)C1COc2c(C3CCC3)ccc(OC)c21

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.35
CYP3A4 P08684 1/20 0.35
MAPK1 P28482 1/20 0.35
PTGDR2 Q9Y5Y4 2/20 0.34
PTGDR Q13258 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
HTR1A P08908 3/20 0.33
PSMB5 P28074 1/20 0.33
DRD2 P14416 1/20 0.33
DRD3 P35462 1/20 0.33
TSHR P16473 1/20 0.33
PTGS1 P23219 1/20 0.33
ALDH1A1 P00352 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ABCB1 P08183 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20480628 0.89 PTGDR2 (0.38) HTR2ACYP3A4MAPK1PTGDR2MEN1
SCHEMBL20480662 0.88 KDM4E (0.40) MAPK1MEN1KMT2ATSHRALDH1A1
SCHEMBL20480480 0.84 KDM4E (0.42) MEN1KMT2ANPSR1PSMB5TSHR
SCHEMBL20480427 0.80 HTT (0.39) HTR2ATSHRALDH1A1SMN1; SMN2
SCHEMBL20480682 0.80 KDM4E (0.38) PTGDR2MEN1KMT2ANPSR1HTR1A
SCHEMBL20480596 0.79 ALDH1A1 (0.37) HTR2AMAPK1PTGDR2HTR1ATSHR
SCHEMBL20478683 0.78 HDAC1 (0.37) PTGDR2PTGDRNPSR1HTR1A
SCHEMBL20480217 0.76 P2RX7 (0.38) MEN1KMT2ANPSR1TSHRALDH1A1
SCHEMBL20480221 0.76 CYP19A1 (0.44) CYP3A4MEN1KMT2AHTR1ATSHR
SCHEMBL20480316 0.74 PSMB5 (0.48) CYP3A4KMT2APSMB5ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10428017-B2 Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use ABBVIE S.Á.R.L. (LU) 2019-10-01 US disclosed
US-20180244640-A1 Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use ABBVIE S.Á.R.L. (LU) 2018-08-30 US disclosed
WO-2018154493-A1 MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE AbbVie S.à.r.l. (LU) 2018-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10428017-B2 Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use CFTR, CLCN2, SCNN1G HTR2A 3843/4885CYP3A4 4723/4885MAPK1 4133/4885
US-20180244640-A1 Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use CFTR, CLCN2, SCNN1G HTR2A 3843/4885CYP3A4 4723/4885MAPK1 4133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.